Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Inventory (2024 - 2025)

ImmunityBio (IBRX) has disclosed Change in Inventory for 2 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 25.02% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a 23.54% decrease, with the full-year FY2025 number at $6.3 million, down 23.54% from a year prior.
  • Change in Inventory was $7.9 million for Q4 2025 at ImmunityBio, up from $63000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $7.9 million in Q4 2025 to a low of -$1.8 million in Q2 2025.